Two winners will be flown from a London airport to spend 2 nights at the Krka Terme Hotel Svoboda Strunjan, a night at the Grand Union Hotel Ljubljana and a night at the Grand Hotel Bled, plus car hire.
To enter, visit www.discoverkrka.co.uk and pick out the differences between the Dalmations.
Ned Flaxman from Krka said: "I’ve only recently joined KRKA and I’m sure like many people I imagined Slovenia to be some far-off country in Eastern Europe. But it’s much closer than you might think - being only a couple hour’s boat ride from Venice.
"I would urge anyone to enter the competition to be in with the chance of winning this truly memorable trip. From the cliffs and stunning beaches of Strunjan to the lively and beautiful city of Ljubljana, Slovenia is a hidden gem just waiting to be discovered."
Andrea Tarr BPharm MSC MRPharmS, the founder and director of Veterinary Prescriber said: "Prescribing is a neglected aspect of veterinary practice. When it comes to making treatment decisions, vets are very poorly supported by their professional organisations, the pharmaceutical industry has a hugely distorting influence and there's a lack of access to really helpful information.
"We're determined to use the expertise in Veterinary Prescriber to change this, and support vets in their use of medicines in the best interests of animals, their owners and the environment.
"With this in mind, we start the year with a learning module of good veterinary dispensing practice."
The module explains what constitutes a well-run dispensary, including how to organise, handle and store medicines correctly. It reviews the legal classifications of medicines, including controlled drugs and the cascade. It also considers why dispensing errors occur and what to do when they happen.
Veterinary Prescriber says its modules are evidence-based, peer-reviewed and independent of the pharmaceutical industry.
Subscription costs £9.95 per month, which you can cancel any time. To subscribe, visit: www.veterinaryprescriber.org
The BSAVA has announced the launch of a free new online publication: BSAVA Guide to the Use of Veterinary Medicines
Edited by Fred Nind and Pam Mosedale, with contributions from experts in the field, has been developed to provide a comprehensive guide to a wide variety of veterinary medicines issues that affect small animal practice. It looks like a very polished production, and should prove a valuable tool for all members of the practice team.
Many infringements of the law relating to the possession, use and disposal of veterinary medicines are criminal offences, and it was the aim of the Editors to produce an authoritative guide to help practitioners stay on the correct side of the law in an area where this can sometimes be problematic.
LegislationAs Fred and Pam noted in the March 2009 issue of Companion: 'Veterinary Medicines Regulations (VMR) change every year, whilst waste disposal provisions and dangerous drugs regulations seem to be updated even more often. This means that what you learned at a course attended last year or from a booklet published two years ago may no longer be accurate.' The format of the BSAVA Guide to the Use of Veterinary Medicines, means that it is capable of being updated as the rules and regulations change, helping veterinary surgeons, nurses, practice managers, receptionists, students and kennel staff to get it right - first time and every time.
StorageEfficient stock control, ambient storage conditions, stock rotation based on expiry dates and correct labelling are just some of the areas that need to be addressed when considering management of the practice dispensary. The section of the guide on Correct storage and dispensary management provides recommendations on how this can be achieved.
DispensingPrescribing and labelling veterinary medicines are activities that every practitioner performs many times a day, and it is important that the detailed legal provisions governing these actions are adhered to. Covering such areas as: who may write a prescription; breaking packaging; and the additional regulations that apply for the supply of Controlled Drugs, the Prescribing and labelling section helps guide the practitioner through this complicated area.
The BSAVA Guide to the Use of Veterinary Medicines is available to all, not just BSAVA members, and the Editors hope will 'provide balm for all those worrying about the practical and legal constraints on the use of veterinary medicines.'
Click here to download the BSAVA Guide to the Use of Veterinary Medicines (pdf 5mb)
Themed 'Controlling Disease Threats at Home and from Abroad’, this year's conference will highlight the increasing importance of OVs in safeguarding the UK’s international trade and in protecting human health through disease surveillance and control.
The conference programme includes dedicated lecture streams aimed at large animal, small animal and equine practitioners. Improve says that lecture content has been tailored to cover areas of key relevance for more than 8,000 OVs due to revalidate their qualifications in March 2019. The programme also includes interactive workshops, including drop-in question and answer sessions offering practical advice and guidance on the revalidation process.
An exhibition of products and services for OVs runs alongside the conference.
David Babington MRCVS, Business Development Director at Improve, said: "This conference remains the only event dedicated to the needs of OVs. They receive industry updates from leading figures in the veterinary sector, attend lectures on OV work from experts and, in so doing, work towards their CPD revalidation requirements. We’re currently finalising a packed programme for this year’s conference and urge OVs to take advantage of our time-limited Early Bird offers and register without delay."
For more information on the Official Veterinarian Conference and Exhibition or to register visit: www.officialvet.com
MSD says the new vaccine reduces the clinical signs of respiratory disease and viral shedding from infection with Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (Pi3V), and that no other UK-licensed BRD vaccine can be administered earlier in life.
According to the company, it also delivers the fastest on-farm protection, with an onset of immunity after administration of 5 days for BRSV and 7 days for Pi3V. The duration of immunity is 12 weeks for both viruses.
MSD Animal Health ruminant veterinary adviser Dr Kat Baxter-Smith MRCVS said: "Early-age protection of calves through intranasal vaccination can help prevent pneumonia and positively impact a calf’s productive future.
"The sooner and faster these young calves can be protected against viral BRD and the permanent lung damage it causes, the better their potential lifetime productivity, be it in terms of delivering expected milk yield in the dairy herd or growth performance on the beef unit1 2."
Kat added that Bovilis Intranasal RSP Live also activates non-specific immunity – stimulating receptors and cytokines in the innate immune system3: "This equates to protection against viral replication in the nasopharyngeal cavity, reduction of virus shedding and protection of the calf against subsequent clinical symptoms3."
MSD says a practical benefit of Bovilis Intranasal RSP Live to farmers is that it can be used on farm up to six hours after mixing with the solvent, which is the longest of all the available intranasal BRD vaccines. Additionally, the new vaccine is supplied as a farm-friendly, easy-to administer nasal suspension product that doesn’t need a specific applicator – although for maximum flexibility a new easy-clean injector and nozzle kit is available for farmers needing to vaccinate multiple animals.
References:
The company says the initiative, which is targeted at veterinary professionals and farmers, will be supported by an extensive social media, advertising and PR campaign.
The social media campaign will take the form of social media content, newsletter articles and images for veterinary practices to use on their social media channels and will include information on the cost of dairy cow lameness and tips to manage lameness.
Rose Jackson BVSc DBR CertVBM MRCVS is the farm clinical director at Scarsdale Vets which has already trialled the new materials. She said: “The ‘Wave Goodbye to Pain’ social media content has ensured that we are able to post eye-catching and thought-provoking content to continue to engage with our clients and raise awareness of the ‘triple works’ approach to lameness in cows, which includes using a NSAID such as Ketofen, alongside a trim and block for a more complete recovery from lameness than trimming alone.”
The ‘Wave Goodbye to Pain’ campaign was launched following a study by Nottingham University which revealed that NSAIDs have a synergistic effect when given alongside effective hoof trimming and blocking to treat lameness1.
The study looked at claw horn disease of the hind foot and found that trimming alone resulted in a 69% rate of return to mobility without lameness in 35 days. Adding a block into an effective trimming protocol raised the success rate to 72%; trimming and administering a NSAID raised it to 76%. Interestingly, using all three techniques together - trimming, applying a block and administering an NSAID - resulted in 85% of cases being successfully resolved (Mobility score or 0 or 1).
Gemma Robinson BVM BVS MRCVS, ruminant veterinary adviser at Ceva Animal Health, said: “The study highlights that effective and prompt pain relief with NSAIDs can quickly help restore animals back to full productivity. Attitudes on the use of pain relief have changed significantly over the last 10 years and dairy farmers can have a positive influence by ensuring they recognise the value of NSAIDs and prioritise their use on-farm. It is important that vets discuss NSAIDs with their clients, both to manage illness and for routine procedures, and our ‘Wave Goodbye to Pain’ campaign will help encourage farmers to think about their current pain management plan, take action and seek help from their vet.
“Some concerns have been raised that the issues associated with antimicrobial resistance and antibiotic administration are causing farmers to avoid the use of all injectable treatments. We need to be clear that NSAIDs are anti-inflammatories, not antibiotics, and it is important they are used for pain management, fever and the clinical signs associated with many common conditions. With zero milk-withhold NSAIDs available - there really is no reason to hesitate when it comes to administering pain relief in otherwise healthy cattle.”
For more information on the ‘Wave Goodbye to Pain’ campaign visit the website designed for farmers (www.wavegoodbyetopain.co.uk), contact your local Ceva territory manager or call 01494 781510.
To request a copy of the ‘Wave Goodbye to Pain’ social media pack (including pre-developed posts and images which you can send out to your own clients), speak to your Ceva territory manager or email: cevauk@ceva.com with your name, practice name and address details.
References
Tuloxxin contains Tulathromycin and Krka says it is based on the same formulation as the market leader.
In cattle Tuloxxin is administered using a single subcutaneous injection; in sheep Tuloxxin is licensed for use in the treatment of foot rot associated with Dichelobacter nodosus and also in pigs for swine respiratory disease (SRD) administered via a single intra-muscular injection. Krka says it is fast-acting, and that the one dose formulation supports compliance and so reduces stress to herds and flocks.
Charlotte Read, Key Account Manager – Farm, at Krka, said: "Whenever Krka launches a generic product, we aim to add some extra value to it. Tuloxxin is a good example. It is based on a tried and trusted active and delivers efficacy; with formulation and delivery method technology at exceptional value. We hope its launch will support vets in their appropriate choice of antibiotic for specific cases. In so doing, they will be protecting their clients’ cattle and profitability while also playing their part in reducing antimicrobial use.”
Tuloxxin is available now from all wholesalers.
Elanco is highlighting new research which shows that using monensin in dairy cows at high risk of developing subclinical ketosis reduces curative antibiotic use by 25%.
According to the company, good herd management before calving is known to mitigate antimicrobial use in cows suffering from subclinical ketosis related conditions, but to date little research has quantified it.
The new research, by the University of Toulouse, was presented to leading cattle vets, academics and representatives of the pharmaceutical industry by veterinary cattle health specialist, Professor Didier Raboisson at the European Buiatrics Forum in Rome in October.1 It showed that using a monensin bolus in cows at high risk of getting subclinical ketosis led to a 25% reduction in antibiotics to treat and cure conditions associated with the metabolic condition.
Fiona Anderson MRCVS of Elanco said: "Responsible use of antimicrobials must be the target for veterinary medicine. Reducing use by whatever means could help improve the antimicrobial resistance situation. This new study shows that using monensin, which is available in the form of a Kexxtone bolus, is a powerful way to cut antibiotic use in the dairy herd. This is in addition to monensin already proven to be a valuable tool to reduce the risk of ketosis and subclinical ketosis and its associated losses in dairy herd productivity and profitability."
Subclinical ketosis is very common. It can affect up to 30% of cows in early lactation with a large variation between herds.2 It can be very costly for a dairy herd. A study from 2015 found that for a 100 cow herd with 30% ketosis, the direct and indirect costs can be around £10,416 or around £347 per affected cow.3
Cows affected by subclinical ketosis are at a higher risk of getting mastitis and metritis. They are also at higher risk of developing displaced abomasum, retained placenta and cystic ovaries and consequently face a higher culling risk. Subclinical ketosis also lowers milk production, reduces conception rates and lengthens calving intervals.4
If ketosis is an issue in a dairy herd, targeted administration of monensin in a Kexxtone bolus to cows at high risk of developing ketosis reduces the incidences of ketosis by 74%.6
The bolus is given three weeks before calving and provides coverage during the main risk period for the condition. Kexxtone uses monensin to improve rumen function and increase glucose delivery. This ultimately increases the energy available and buffers the dairy cow against the tendency to drop into negative energy balance.5
To make a big difference to clients’ profitability, Fiona encourages vets to not just consider the traditional nutritional intervention and the emergency treatment of ketosis cases, but to develop an effective strategy to highlight cows at risk of subclinical ketosis and to take targeted preventative action. She said: "Vets who can offer positive interventions to subclinical ketosis and its associated losses in the dairy herd are going to be increasingly important to their clients’ herd health planning."
Vetsonic UK has announced the addition to its range of Vetericyn Super 7+, a brand new umbilical cord dry-out solution for use in calves, lambs, piglets, foals, kids and puppies which is designed as an alternative to iodine.
Vetsonic says that because Super 7+ contains no iodine, it won't encourage licking by iodine-deficient mothers, which can cause serious damage to the navel. It is also an ideal alternative for handlers who are prone to iodine allergies.
The company points to a US study conducted by Auburn University in which Super 7 + demonstrated more than double the desiccation efficacy in the first 24 hours when compared to 7% tincture of iodine.
Super 7+ contains a dye for easy identification of treated animals and the company says it is environmental friendly, safe, non-flammable and non-corrosive with no toxic fumes.
Super 7 + is now available through veterinary wholesalers and direct from Vetsonic (UK) Ltd, either in a 500 ml spray bottle (box of 6) or a 3.78 litre bottle for dipping.
For more information, visit www.vetsonic.com
Amongst the speakers were Catherine Oxtoby MRCVS, Risk Manager at the Veterinary Defence Society, and Dr Huw Stacey, director of clinical services at Vets4Pets.
Dr Stacey explained how Vets4Pets and Companion Care practices are embracing a culture of sharing information when things don’t go according to plan in practice.
He said: "We all face challenges in the workplace, and this event focused on how different professions can share ideas and good practice and how they find solutions to any challenges.
"The culture of aviation and maritime is one of minimising risk and putting safety first, and it is fascinating to compare their approach to that found in medicine and veterinary.
"One common theme we discussed was the wellbeing of both professionals and patients or clients, with tiredness being at the top of the list of things that can negatively affect wellbeing and performance.
"Both aviation and maritime recognised that long shifts, particularly overnight, needed to be reduced in order to improve the outcome for everyone.
"In veterinary and human medicine, tiredness and long shifts are often worn as a badge of honour and being tired at work was something that should be admired, rather than addressed.
"But, tired vets are effectively neglecting themselves and their own wellbeing, which in turn leads to pets not receiving the best level of care in practice.
"This is something we’re taking seriously at Vets4Pets and Companion Care, and we’re currently looking at ways to decrease the risk of overworked and tired vets and vet nurses."
Another area of discussion was around the reporting of near misses and when things don’t go right, and how veterinary professionals need to identify and share the learnings from these events, not only within their practice, but with the wider profession too.
He said: "We need to continually emphasise the concept of a ‘just’ culture, to ensure our colleagues feel confident about reporting incidents open and honestly."
"It is not in the interests of the professional, the patient or the client to bottle things up, and at Vets4Pets and Companion Care we’re encouraging all of our practices to adopt the VDS VetSafe system, which provides a mechanism for sharing incident reports across the profession, enabling us all to learn from them to the benefit of our patients."
According to statistics from the RCVS, almost 40% of veterinary surgeons that have registered in the UK since 2005 qualified from veterinary schools elsewhere in the EU.
Of course, it's not just in general practice that veterinary surgeons and veterinary nurses from other EU member states make such an important contribution. They work across all areas of veterinary science, including the fields of animal health and welfare, animal disease surveillance, scientific research and education, wildlife conservation, and public health and food safety.
Figures from the Veterinary Public Health Association (VPHA) estimate that over 90% of vets in meat hygiene services are non-British EU citizens.
To highlight the impact of Brexit on the veterinary profession, the BVA has written to the Secretary of State, Liz Truss MP, and to Ministers in Scotland, Wales and Northern Ireland, requesting an early statement to the effect that non-British EU vets and vet nurses who are currently living, studying or working in the UK will continue to be able to do so in future.
BVA is also seeking reassurance for UK veterinary professionals working and studying in other EU member states.
BVA President Sean Wensley said: "It is not yet possible to comment on the reality of ‘Brexit’ since much will depend on forthcoming negotiations and the decisions that will be taken by the Government regarding, for example, whether or not to maintain existing EU legislation and rules. However, we recognise that these unanswered questions are having a profound impact on many of our members – particularly members who are non-British EU citizens, or have family members who are, and members who work alongside colleagues from other European Member States."
In the letters, Mr Wensley wrote: "I am sure there are many significant issues that your Department needs to consider [and] given the profound personal impact that the uncertainty caused by the referendum outcome is having on some of our members, we wanted to contact you at the earliest opportunity. In the forthcoming negotiations about the future relationship between the UK and the EU, we strongly urge you to make the case for all EU citizens and EU-qualified veterinary surgeons and nurses to have ongoing rights to live, work and study in the UK."
In the letter to the Northern Ireland (NI) Minister of Agriculture, Environment and Rural Affairs Michelle McIlveen MLA, the BVA President and BVA NI Branch President Seamus O’Kane highlighted NI’s land border with EU member state the Republic of Ireland and called for the maintenance of the Common Travel Area to facilitate movement in an all-island context for both work and study purposes.
VPHA President Lewis Grant said: "Due to the particular focus on public health in many European veterinary degree courses, EU vets make an enormous contribution to both public health and animal health and welfare in the UK - often behind closed doors, monitoring and protecting public health in Approved Premises as well as welfare at slaughter to ensure slaughterhouses meet the standards that are required by law and expected by the public. Without their input and expertise, it would be difficult to ensure that Statutory requirements within the food industry are complied with."
Reporter Andy Davies spoke to Charlotte Debbaut MRCVS, a veterinary surgeon from Belgium working at the Tindale Veterinary Practice in Gloucestershire, where there are 13 vets with eight different nationalities. He also interviewed Matthew Pugh MRCVS and Ovidiu Oltean MRCVS from Belmont Veterinary Centre, a mixed practice in Hereford which employs five foreign nationals out of a team of 13 veterinary surgeons.
Finally, he talked to John Blackwell MRCVS at Brownlow Veterinary Group in Shropshire, where Brexit had already caused a Croatian member of his team to refuse a permanent position and return to Ireland.
Congratulations to the RCVS and BVA press offices, who will have been hard at work behind the scenes.
See: https://www.channel4.com/news/brexit-affecting-vet-recruitment
Tolracol is a 50mg/ml suspension of toltrazuril which can be used in all three species to prevent coccidiosis infections in youngstock on farms with a history of the disease.
Krka’s head of sales and marketing, Killian Gaffney said: "Coccidiosis can have a devastating impact on young animals, resulting in ill-thrift, weight loss and potentially death, making its prevention a vital component of herd or flock management.
"Importantly, this is a tri-licence single dose product which requires vet prescription. The involvement of the vet in prescribing coccidiostats is important as their use should be part of a whole management approach to prevention."
Krka says Tolracol should be used ahead of the peak infection period on farms with a pre-existing coccidiosis problem, with it recommended for use in neonatal pigs at three to five days old and as soon as required in calves and lambs.
Mr Gaffney added: "This product has been proven in trials and offers a cost-effective option for farmers, it is also easily administered which farmers will find attractive. Krka is launching a new farmer campaign to support Tolracol.
"With lambing and spring calving now taking place across the country vets are likely to be asked in the coming weeks and months about coccidiosis prevention. Tolracol provides another valuable tool in the armoury when it comes to preventing this nasty condition and should be considered as a first-choice product."
For more information, see the SPC or contact Krka UK Limited on +44 (0) 2071 646 156.
Zoetis has announced the launch of Zulvac SBV, a new Schmallenberg vaccine licensed for use in cattle and sheep in two doses at a three week interval, the second at least two weeks before mating.
Zulvac SBV is licensed for use in cattle and sheep in two doses at a three week interval, the second at least two weeks before mating.
Duration of immunity is six months in cattle and seven in sheep. At the recommended vaccination timing, this covers the window of susceptibility during pregnancy; in sheep from day 28 to 56, and days 70 to 150 in cattle. Animals infected during these periods are at risk of malformed offspring and subsequent stillbirth.
The company says vaccination combined with insecticidal measures to control the midge vector remains the most effective way of protecting the population1 and ensuring a more unified level of immunity.
Zoetis vet Carolyn Hogan said: "Although SBV is now considered to be an enzootic pathogen in England and Wales, there is plenty of evidence that seroprevalence at farm level – particularly on sheep farms - varies. As immunity wanes, the proportion of herds and flocks naïve to SBV and at risk via introduction of naïve replacements increases. So the risk of reinfection in assumed enzootic areas is potentially underestimated2.
"Culicoides midges, the SBV vector, are widespread in Europe and move easily between farms and regions, allowing rapid spread of infection."
Carolyn says that whilst there have been no confirmed diagnoses of congenital abnormalities in calves or lambs from APHA in 2014 or 2015, unconfirmed anecdotal cases have been reported.
"We do not know whether our ruminant population is immune or susceptible and neither do we know if another SBV challenge will appear. Vaccination remains the most effective way of ensuring valuable livestock are protected."
Supplies are available immediately.
Novartis Animal Health has announced the launch of Strenzen, an oral water medication for pigs, indicated for the treatment of gastrointestinal infections caused by Escherichia coli, Clostridium perfringens and Salmonella Typhimurium, and for respiratory tract infections caused by Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
Strenzen contains contains a combination of amoxicillin trihydrate (500 mg/g) and potassium clavulanate (125 mg/g) in ratio of 4:1. Novartis says it is ideally suited for the treatment of post-weaning infections in pigs.
According to the company, the combination of amoxicillin and clavulanic acid broadens the performance of amoxicillin1,2, especially against resistant strains of bacteria capable of producing ß-lactamase enzymes. Certain bacteria are able to produce ß-lactamase enzymes as a protection mechanism, making the amoxicillin molecule ineffective against them. The clavulanic acid in Strenzen binds to the molecules of the ß-lactamase enzyme, ensuring the amoxicillin remains unaffected and free to attack bacteria. Prof. Dominiek Maes, DVM, MSc, MS, PhD, Dipl. ECVPH, Dipl. ECPHM, from the Porcine Health Management Unit of the Ghent University, Belgium said: "Weaning is a stressful event for piglets and there are several opportunistic diseases that can impact them during this period. The challenge with E. coli and S. suis infections is that in many countries there are currently no commercial vaccines available with proper efficacy. I believe Strenzen can indeed be very helpful in managing those infections which are so prevalent after weaning."
Novartis says Strenzen is rapidly excreted, leading to a withdrawal period of one day, which in turn maximizes production flexibility for pig producers. In addition, the water-soluble formulation of Strenzen ensures that treated pigs get a therapeutic dose even when they stop eating, making it an ideal treatment for sick pigs with compromised appetites.
Recent field trials on infected farms in Spain and the Czech Republic demonstrated that Strenzen-treated pigs give better production performance, better economic returns and require less medical intervention3,4,5. The reduction of the overall amount of antibiotics needed to treat severe post-weaning infections not only saves producers the costs of the labour and the medication, but is also important in regard to the development of resistance in bacteria.
Dr. Ulrich Klein, Global Technical Services Manager, Novartis Animal Health said: "With the launch of Strenzen, Novartis Animal Health demonstrates its commitment to continually broadening our product portfolio to address the specific needs of farmers and food producers. Strenzen has the ideal spectrum for the treatment of post-weaning infections, delivering better productivity results than current therapies for those infections."
David Chalkley MRCVS faces four alleged charges:
At the start of the hearing Mr Chalkley made no admissions as to the charges but he had made an application for an adjournment based on undertakings to remove himself from the Register and never to apply to be restored to the Register.
In addressing the Committee on behalf of Mr Chalkley, his counsel said that Mr Chalkley denied all charges of dishonesty, that there was no evidence of harm to animals as a result of the alleged conduct, that there had been no complaint from the client and that he had repaid all the sums he had received for tuberculin testing on the farm in question.
His counsel also submitted that a full hearing would be expensive and time-consuming, and that it would serve no useful purpose as animal welfare and the protection of the public would be served by Mr Chalkley’s proposed undertakings.
Counsel on behalf of the RCVS confirmed that the College did not oppose the application and confirmed that the Animal Plant and Health Agency did not object.
However, the Disciplinary Committee concluded that because the case concerned issues of alleged dishonesty in veterinary certification over a prolonged period of time and the importance of public trust in the accuracy and reliability of that process, there was a need to hold a full, public hearing into Mr Chalkley’s alleged conduct.
Ian Arundale, chairing the Committee and speaking on its behalf, said: “The Committee expressed no view as to whether the allegations could be substantiated or not and it recognised that the process of determining the allegations would be burdensome for many, particularly the respondent.
"It was satisfied, however, that a reasonable and fully informed member of the public would be disturbed to learn that allegations of this kind had not been the subject of a formal determination by the Disciplinary Committee. The respondent’s own interests had to take second place to this important public interest.
“The Committee therefore declined to accept the application to adjourn this inquiry [until an unspecified date] and directed that arrangements should now be considered for the listing of a hearing in this case.”
It is expected that the full hearing will take place in spring 2021.
Cefshot is indicated for treatment of subclinical mastitis at drying off with action against Gram positive and Gram negative bacteria.
Jude Roberts MRCVS from Zoetis says this makes possible three-way selective dry cow therapy with products from the company's dry cow portfolio: "With evidence-based triage, this covers teat sealant solo, in combination with narrow spectrum cloxacillin, or now with broader spectrum long-acting cephalonium.
"This is in keeping with the trend from milk buyers for increasing precision in the use of antibiotic dry cow therapy, and only when it is justified in the first place."
Dry periods longer that 54 days require milk withhold for 96 hours. For shorter dry periods, milk withhold is 58 days. Meat withhold period is 21 days.
Cefshot is available in multiples of 24 and 120 tubes, for delivery September onwards.
MSD Animal Health has launched Bovilis IBR Marker Inac, an inactivated marker vaccine for use in the control of Infectious Bovine Rhinotracheitis (IBR).
The company says the new product complements Bovilis IBR Marker Live and creates a range now offering greater simplicity and additional flexibility for veterinary surgeons seeking optimum control protocols for their clients' herds.
MSD Animal Health ruminant veterinary adviser Drew McGurren MRCVS said: "Farmer compliance is an important part of any successful vaccination programme. With this extended Bovilis IBR Marker programme, farmers can now start IBR vaccination of their cattle from three months of age with a single shot primary course of Bovilis IBR Marker Live, easily followed by boosters every six months using a single dose of either Bovilis IBR Marker Live or Bovilis IBR Marker Inac. Both primary course and boosters can be administered by the same intramuscular route.
"Alternatively, Bovilis IBR Marker Inac can be administered to cattle from three months of age as a primary course of two injections four weeks apart. The programme then follows a six monthly single dose booster regime.
"The availability of Bovilis IBR Marker Inac provides a simple control option in defined farm situations, not least where an alternative to the live vaccine is preferred or required. Overall, we see this development adding convenience, ease of use and flexibility for veterinary surgeons as they work with their clients to control a significant disease threat in dairy and beef cattle in the UK."
Bovilis IBR Marker Inac is a prescription-only medicine (POM-V). The product is available from wholesalers now in 10 and 50 dose vials. For further information, contact the MSD Animal Health Veterinary Support Group on 01908 685685.
The disease had been identified as a priority by the Wales Animal Health and Welfare Framework Group.
Further details will be announced in the coming months following ongoing discussions with industry representatives.
The Minister said: "Sheep scab has significant economic consequences for sheep producers and animal welfare issues for sheep. It is one of the most contagious disease of sheep in Wales and eradicating it is a priority for us and the industry.
"I’m pleased to be able to announce £5m Rural Development Programme funding will be used to help support the industry tackle the disease. Eradicating the disease has the potential to deliver significant lasting economic benefits for the sector at a particularly challenging time as we prepare to leave the European Union."
To mark today's European Antibiotic Awareness Day 2010, the British Veterinary Association is warning veterinary surgeons in the UK that failure to use antimicrobials responsibly could result in their use being restricted.
The BVA promotes the responsible use of antimicrobials and last year published a poster and guidance for vets: 'Responsible use of antimicrobials in veterinary practice: the 8-point plan'. According to the association, the poster received very positive feedback from across the UK and from the Federation of Veterinarians of Europe (FVE).
Concerns regarding resistance to antimicrobials and antibiotics span both the human and animal medicine fields and in 2008 the Chief Medical Officer called for a ban on the use of certain types of antibiotics in animals in order to protect their activity in humans.
Furthermore some EU Member States already restrict the availability of antimicrobials to veterinary surgeons and adopt a strict formulary approach to the medicines that they can prescribe. The BVA says it is concerned that this trend will reach the UK and the freedom of vets to prescribe according to their clinical judgement will be restricted.
Harvey Locke, President of the BVA, said: "Antimicrobial resistance is an enormous problem for both human and animal health. As veterinary surgeons we have a duty to use these medicines responsibly for the good of animal health and welfare as well as public health.
"The BVA's poster on responsible use should be displayed in veterinary practices across the UK as a constant reminder, and I would urge all vets to refer to it.
"Failure to heed the message of responsible use could result in vets losing the right to prescribe certain medicines, which could have a significant impact on animal health and welfare.
"On Antibiotic Awareness Day our message to vets is clear: use them responsibly or lose them."
Prevexxion RN is composed of a serotype-1 construct vaccine which Boehringer says offers a unique balance between safety and efficacy against the most virulent types of Marek’s disease virus strains.
Prevexxion RN+HVT+IBD is a solution combining Prevexxion RN and Vaxxitek HVT+IBD in one ampoule. It is designed to meet the needs of customers in long-life bird segments with protection from the hatchery.
Prevexxion RN vaccines are available in ampoules of 1000, 2000, and 4000 doses, frozen in liquid nitrogen.
Jerôme Baudon, Head of Poultry at Boehringer Ingelheim, said: “Our Prevexxion RN range provides value through innovation to Marek sensitive poultry producers looking for continuous live production productivity improvement and effective protection. Field and lab experiments conducted worldwide demonstrated its safety, efficacy and its strong, early, and long-lasting protection through the lifespan of the birds and against very virulent Marek’s disease challenge.
Prevexxion RN is the new golden standard for Marek's disease vaccination programs2”.
For more information, contact your Boehringer Ingelheim representative.
Reference
The Ruminant Wellbeing Achievement Award will be offered to a practising veterinary surgeon or a researcher in veterinary science, animal science or related disciplines to recognise his/her achievements in advancing the well-being of ruminants.
The Ruminant Wellbeing Research Award will be offered to a recent PhD graduate in veterinary science, animal science or related disciplines that made an exceptional contribution to the scientific knowledge on ruminant well-being.
The winners will be awarded with a €10,000 cash prize. Travel expenses to attend the meeting and awards ceremony (which coincides with the World Buiatrics meeting) will also be covered.
Scott Deakin, Metacam brand manager at Boehringer said: "Farm animal wellbeing is at the heart of efficient and effective production and Boehringer is delighted to have led the way in raising the importance of this over the last 10 years and is committed to doing so for the next 10 years and beyond.
"By linking with the World Buiatrics Association for the first time and offering two awards at the Wellbeing Forum, we believe the company is offering an exciting and valuable opportunity for vets and we look forward to receiving a large number of interesting applications."
Veterinary surgeons can apply directly or nominate a colleague at: www.farmanimalwellbeing.com.
An independent jury will decide on the winner.
The deadline for applications is 28th February 2018.
Elanco Animal Health has announced that there have been extensions to the withdrawal periods for Dectomax (doramectin) 10 mg/ml Solution for Injection and Micotil (tilmicosin) 300 mg/ml Solution for Injection.
For Dectomax injectable, meat withdrawal for cattle and sheep will be extended to 70 days and pigs to 77 days. For Micotil, sheep milk withdrawal will be extended to 18 days and milk from cows during the dry period or from pregnant heifers should not be used for human consumption until 36 days after calving.
Elanco is reminding veterinary surgeons and SQPs that they may continue to prescribe according to the current label but it is good practice to implement revised withdrawal periods. The company is also taking this opportunity to highlight the importance of getting into the habit of double-checking withdrawal periods when administering drugs, because they do change from time to time in the light of new knowledge.
CCTV will be required in all areas where live animals are present, with unrestricted access to footage for Official Veterinarians.
In addition, the Government has also announced that it will be modernising statutory animal welfare codes to reflect enhancements in medicines, technology and the latest research and advice from veterinary surgeons. The codes will remain enshrined in law and the first to be updated will cover chickens bred for meat.
Consultations on these proposals have been launched this morning (https://consult.defra.gov.uk/farm-animal-welfare/cctv-in-slaughterhouses/ and https://consult.defra.gov.uk/animal-health-and-welfare/code-of-practice-for-the-welfare-of-meat-chickens/)
Environment Secretary Michael Gove said: "We have some of the highest animal welfare standards in the world and the actions I am setting out today will reinforce our status as a global leader.
"As we prepare to leave the EU, these measures provide a further demonstration to consumers around the world that our food is produced to the very highest standards."
BVA President Gudrun Ravetz said: "Today’s announcement is extremely welcome. We have been campaigning on this issue for a number of years and this announcement represents a huge win for animal health and welfare in England.
"Mandatory CCTV in all areas of slaughterhouses will provide an essential tool in fostering a culture of compassion that could help safeguard animal welfare and we are particularly pleased to see a commitment to Official Veterinarians having unrestricted access to footage.
"Vets' independence and unique qualifications help ensure that the UK will continue to have the highest standards of animal health, welfare and food safety.
"We recognise that the cost of installing CCTV may be a burden for some very small abattoirs, but it is important that the animals we farm for food have both a good life and a humane death and CCTV has a key role to play in ensuring these requirements are met."
Gudrun added: "We welcome the consultation to update welfare codes for farmed animals and pets, many of which are in urgent need of updating to reflect the latest animal welfare science and good practice. We are keen to see Defra working with the veterinary profession, industry and all relevant stakeholders to ensure vital welfare codes are brought up to date."
John Tasker of the British Veterinary Poultry Association said: "BVPA are committed to supporting research and implementation of best practice in all aspects of poultry production, including welfare on farm and in the abattoir. We look forward to cooperating fully with Defra in development and implementation of these new initiatives. The British poultry industry has some of the highest welfare standards in the world and seeks to continually update and refine its practices in the light of new research, and to maintain public confidence in the industry."
Photo: Lititz, Pennsylvania. Hoisting a slaughtered steer in Benjamin Lutz's slaughterhouse, 1942. Wikipedia.
MSD Animal Health has announced the launch of Cepralock, a new teat sealant to complement its dry cow intramammary product Cepravin Dry Cow and wider Dairy Herd Health portfolio.
The company says the new product is designed for use at drying off, with or without a dry cow intramammary antibiotic, and provides an important inert barrier in the teat canal to reduce significantly the risk of bacterial infection of the udder during the dry period.
Cepralock is supplied in tubes with the option of short nozzles that are designed to help avoid the risk of teat damage and incorrect administration beyond the teat canal.
The launch is also being accompanied by dry cow therapy training and a support programme for veterinary practitioners and their dairy farmer clients. This will include diagnostics and data analytics, and training will have a significant focus on correct administration and removal of teat sealant after calving, allowing vets to provide adequate reassurances to their clients around product use.
MSD Animal Health technical adviser Martin Behr said: "The dry period is a critical time for vets as they seek to help their clients in the battle to combat mastitis, which remains a significant drain on dairy herd profitability. It provides an ideal opportunity to clear up existing bacterial infections in the udder with the use of intramammary antibiotics, but it is also vital to prevent new infections over the period.
"Cows do have their own natural physical defence against infection in the form of the keratin plug that forms in the teat canal after drying off, but this is not always sufficiently effective. In a recent study it was shown that only 50% of 500 examined quarters had a fully developed keratin plug within 10 days of drying off, whilst 20% of teats remained open into the second half of the dry period. This is significant because the majority of clinical cases of mastitis that occur during the dry period do so within the first three weeks.
"Correct use of a teat sealant at drying off, immediately after the administration of the dry cow intramammary if used, will provide an effective physical barrier for the duration of the dry period, significantly reducing the chances of new infections of the udder."
According to MSD, it is estimated that less than half of dairy cows are currently given a teat sealant at drying off, despite the concept being established for a number of years and numerous farm studies providing strong evidence of their efficacy.
Martin added: "The potential return on investment for dairy farmers of correctly applied teat sealants is clear. A single case of mastitis is estimated to cost between £70 and £250 and the average UK dairy herd suffers somewhere in the region of 50 to 60 cases per 100 cows per lactation. A correctly applied dry cow therapy programme, including the use of teat sealants, will significantly reduce the incidence of clinical mastitis, thereby providing a demonstrable return on investment.
"At MSD Animal Health we are keen to help veterinary practitioners promote best practice in dry cow therapy, including the adoption of the correct protocols and application procedures. Therefore we are supporting the launch of Cepralock with the offer of Continuous Professional Development for veterinary practitioners on all aspects of dry cow therapy, including correct use of teat sealant and its removal after calving."
Cepralock teat sealant is available to veterinary practices in packs of 24 tubes and 120 tubes.
For more information about Cepralock or MSD's Dry Cow Management Support package for vets and farmers, contact your Account Manager.